Literature DB >> 22522029

Inhibitory effects of β-tricalciumphosphate wear particles on osteocytes via apoptotic response and Akt inactivation.

Yun Zhang1, Ming Yan, Aiyue Yu, Hongjiao Mao, Jinping Zhang.   

Abstract

Wear debris-induced osteolysis, a major contributing factor of orthopedic implant aseptic loosening, affects long-term survival of orthopedic prostheses following joint replacement and revision surgery. Pathogenic effects of wear debris on various cell types including macrophages/monocytes, osteoblasts, and osteoclasts have been well studied. However, the interactions between wear debris particles and osteocytes, which make up over 90% of all bone cells, have not been clearly illustrated. Here, we explored the biological effects of endotoxin-free beta-tricalciumphosphate (β-TCP) wear particles with the average diameter of 1.997 μm (range 1.3-3.2 μm) on osteocytes in vitro. Our results showed that 24 h or 48 h incubation of β-TCP particles dose-dependently inhibited cell viability of osteocytes MLO-Y4. Alternatively, β-TCP particles treatment for 24 h significantly increased the osteocytic marker SOST/sclerostin mRNA expression and the release of inflammatory cytokines including TNF-α and IL-1β into the culture media, but decreased the mRNA expression of another osteocytic marker dentin matrix protein-1 (DMP-1). Furthermore, these osteocytes dysfunctions were accompanied by F-actin disassembly, cell apoptosis, sustained enhancement of intracellular reactive oxygen species (ROS) and mitochondrial injury upon β-TCP particles stimulation. In addition, β-TCP particles also caused Akt inactivation at Ser473 resides with a dose- and time-dependent pattern. Taken together, β-TCP wear particles could cause osteocytes dysfunctions, which may be mediated by apoptotic death and Akt inactivation in MLO-Y4 cells. These findings strongly suggest that osteocytes may play an important role in the β-TCP wear particles-induced osteolysis, and provide valuable insights for understanding the molecular mechanisms of osteocytes death involved in tissue damage during bone cement and intolerance of cemented prostheses.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22522029     DOI: 10.1016/j.tox.2012.04.002

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  6 in total

Review 1.  A review of osteocyte function and the emerging importance of sclerostin.

Authors:  Jocelyn T Compton; Francis Y Lee
Journal:  J Bone Joint Surg Am       Date:  2014-10-01       Impact factor: 5.284

2.  Bergapten prevents lipopolysaccharide mediated osteoclast formation, bone resorption and osteoclast survival.

Authors:  Mingxia Zheng; Yongliang Ge; Haiyu Li; Ming Yan; Jin Zhou; Yun Zhang
Journal:  Int Orthop       Date:  2013-12-04       Impact factor: 3.075

3.  Reduction of SOST gene promotes bone formation through the Wnt/β-catenin signalling pathway and compensates particle-induced osteolysis.

Authors:  Zai Hang Zhang; Xin Yu Jia; Jing Yi Fang; Hao Chai; Qun Huang; Chang She; Peng Jia; De Chun Geng; Wei Xu
Journal:  J Cell Mol Med       Date:  2020-03-05       Impact factor: 5.310

Review 4.  Physiological and pathological osteocytic osteolysis.

Authors:  Elena Tsourdi; Katharina Jähn; Martina Rauner; Björn Busse; Lynda F Bonewald
Journal:  J Musculoskelet Neuronal Interact       Date:  2018-09-01       Impact factor: 2.041

5.  Osteocytic cells exposed to titanium particles increase sclerostin expression and inhibit osteoblastic cell differentiation mostly via direct cell-to-cell contact.

Authors:  Hao Chai; Zai Hang Zhang; Jing Yi Fang; Chang She; De Chun Geng; Wei Xu
Journal:  J Cell Mol Med       Date:  2022-06-28       Impact factor: 5.295

6.  Sclerostin-Mediated Impaired Osteogenesis by Fibroblast-Like Synoviocytes in the Particle-Induced Osteolysis Model.

Authors:  Supriya Jagga; Ashish Ranjan Sharma; Yeon Hee Lee; Ju-Suk Nam; Sang-Soo Lee
Journal:  Front Mol Biosci       Date:  2021-06-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.